Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

Exclusion Criteria13

• History of meningococcal vaccination B.
• History of anaphylaxis post vaccination.
• Known allergy to any components (active substances or excipients) of both vaccines.
• Patients who cannot stop antibiotics 3 days before blood collection.
• Participants who have received any another vaccines within 4 weeks prior to immunization or who are planning to receive any vaccine within the first 7 months of the study (except the meningococcal ACWY vaccine, the anti-pneumococcal vaccine, the Haemophilus influenzae type B vaccine, the anti-Covid-19 vaccine), annual influenza vaccination which is permitted 2 weeks before and after each vaccination visit of the study and then allowed at any time during the study follow up).
• Parenteral Ig within the 3 months prior to VS or planned during the study.
• Chemotherapy agents within 6 months prior M0 or planning to take any during the study.
• Steroids (\> 10mg/day; \> 14 days) within the month preceding M0 or planning to take any during the study.
• Any pathology or condition that may impair the immune response, apart from splenectomy: immunosuppressive therapy in progress or in the 6 months prior to inclusion, hematopoietic stem cells allo / autograft, primary immunodeficiency, nephrotic syndrome, evolutive cancer, cirrhosis, known infection to HIV;
• Thrombocytopenia or any coagulation disorder contra-indicating intramuscularly injections.
• Pregnancy, breastfeeding or positive pregnancy test up to 7 months after inclusion.
• Severe acute febrile illness within the week before inclusion.
• Registration for any other clinical trial throughout the trial period except observational study.